<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>12481499</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>LÃ³pez Serrano, A</dc:author>
<dc:author>Moreno-Osset, E</dc:author>
<dc:author>del Val Antonana, A</dc:author>
<dc:author>Ortiz Polo, I</dc:author>
<dc:description xml:lang="en">Hepatocellular carcinoma develops in more of 90% of patients in the setting of cirrhosis. The increasing prevalence seems related with the wide-spread distribution of hepatitis C virus infection, as 80% of cases arise on chronic infection caused by this agent. Either conventional resection or orthotopic liver transplantation are often curative but suitable for few patients, If the surgical approach is not adequate, percutaneous ablation using ethanol injection or radiofrequency current may be considered. However, only 15-20% of patients can benefit from these therapies. Chemoembolization is considered when the previous options are contra-indicated but benefits on survival are still a matter of debate. The impact of new agents as tamoxifen, interferon o diverse chemotherapies on both survival and symptoms also remains to be stablished.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2002 Oct </dc:date>
<dc:title xml:lang="es">Tratamiento del carcinoma hepatocelular.</dc:title>
<dc:title xml:lang="en">[Treatment of hepatocellular carcinoma].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
